FDA slaps a hold on Moffitt’s next-gen CAR-T as regulators demand another delay on clinical work — shares crater
Close to a year-and-a-half after tapping the brakes on one of its preclinical programs to do some added genetic engineering work on their next …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
